EyePoint, Inc. (EYPT)
| Market Cap | 36.91M -95.5% |
| Revenue (ttm) | 2.79M -94.6% |
| Net Income | -306.64M |
| EPS | -3.76 |
| Shares Out | 86.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,497,298 |
| Open | 0.4300 |
| Previous Close | 0.4300 |
| Day's Range | 0.4200 - 0.4388 |
| 52-Week Range | 0.3860 - 19.1100 |
| Beta | 1.68 |
| Analysts | Buy |
| Price Target | 25.91 (+5,952.32%) |
| Est. Earnings | Nov 4, 2026 |
About EYPT
EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet ... [Read more]
Financial Performance
In 2025, EyePoint's revenue was $31.37 million, a decrease of -27.50% compared to the previous year's $43.27 million. Losses were -$231.96 million, 77.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for EYPT stock is "Buy." The 12-month stock price target is $25.91, which is an increase of 5,952.32% from the latest price.
News
EYPT SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving EyePoint Pharmaceuticals
EyePoint described its Phase 3 wet AMD trials as designed in close alignment with the FDA. LUCIA then missed its primary endpoint, and LUGANO's favorable result depended on excluding nine DURAVYU pati...
EyePoint downgraded to Hold from Buy at Laidlaw
Laidlaw downgraded EyePoint (EYPT) to Hold from Buy without a price target after the second of the two Duravyu in wet AMD Phase III studies failed to meet the primary…
EyePoint price target lowered to $1 from $5 at RBC Capital
RBC Capital analyst Lisa Walter lowered the firm’s price target on EyePoint (EYPT) to $1 from $5 and keeps a Sector Perform rating on the shares. The LUCIA miss was…
EyePoint downgraded to Neutral from Outperform at Mizuho
Mizuho downgraded EyePoint (EYPT) to Neutral from Outperform with a price target of 50c, down from $39. The firm cites the negative Phase 3 LUCIA study results for lead asset…
EyePoint downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tessa Romero downgraded EyePoint (EYPT) to Underweight from Neutral without a price target The firm cites the company’s first Phase 3 trial evaluating Duravyu in wet age-related macul...
Chardan puts EyePoint target under review after trial miss
Chardan notes that EyePoint’s (EYPT) LUCIA trial missed its BCVA non-inferiority primary endpoint, which “closes the wet AMD path.” EyePoint is cutting 53% of its workforce and Duravya in DME…
EyePoint downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded EyePoint (EYPT) to Neutral from Buy with no price target following the second pivotal failure of Duravyu. EyePoint is now focused on DME, but the firm expects investors…
EyePoint downgraded to Hold from Buy at Jefferies
Jefferies analyst Faisal Khurshid downgraded EyePoint (EYPT) to Hold from Buy with a price target of $1, down from $8, after the Phase 3 LUCIA study of Duravyu in wet…
EyePoint price target lowered to $4 from $17 at Citi
Citi analyst Yigal Nochomovitz lowered the firm’s price target on EyePoint (EYPT) to $4 from $17 and keeps a Buy rating on the shares after the LUCIA study missed the…
This Biotech Stock Sinks Below $1 After Key Eye Drug Fails and Staff Is Slashed. Why There's Still Hope.
EyePoint stock is heading for its largest single-day percentage drop on record.
EyePoint Transcript: Study result
LUCIA missed its BCVA non-inferiority endpoint, though DURAVYU improved vision, reduced treatment burden by 38% and showed strong anatomic control with a favorable safety profile. Focus shifts to phase III DME trials, with topline data expected in Q4 2027.
EyePoint Press release: Study result
EyePoint issued a press release on October 19, 2026, disclosing material business information to investors.
EyePoint Slides: Study result
EyePoint has posted slides in relation to its latest quarterly earnings report, which was published on October 19, 2026.
EyePoint to reduce workforce by 53%
EyePoint (EYPT) announced a strategic prioritization designed to reduce operating expenses and focus resources on its late-stage program for Duravyu in diabetic macular edema, or DME. This strategic r...
EyePoint Announces Strategic Prioritization
WATERTOWN, Mass., Oct. 19, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with s...
EyePoint reports LUCIA trial did not achieve primary endpoint
EyePoint (EYPT) announced topline results from LUCIA, the second pivotal Phase 3 clinical trial of Duravyu for the treatment of wet age-related macular degeneration, or wet AMD. In LUCIA, despite…
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
– LUCIA did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label aflibercept control, despite demonstrating visual improvement – – Key secondary endpo...
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with seriou...
EyePoint Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Recent phase III data showed strong secondary outcomes and safety for a novel wet AMD therapy, despite missing the primary endpoint due to unusual control arm results. A second pivotal trial, LUCIA, will address these findings with data expected in Q4 2026, supporting a potential NDA in 2027.
EyePoint Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Strong secondary outcomes in the LUGANO trial showed reduced treatment burden and good safety, despite missing the primary endpoint due to an unusual control arm result. The upcoming LUCIA trial will address these findings with more robust analyses, and positive results are expected to support regulatory approval.
EyePoint Transcript: Citigroup’s Biopharma Back to School Summit 2026
DURAVYU's phase III program in wet AMD and DME shows strong safety, reduced injection burden, and promising secondary endpoints, despite a primary endpoint miss in LUGANO attributed to randomization. LUCIA results are expected in Q4, with regulatory submission planned for the first half of next year.
EyePoint Slides: Corporate presentation
EyePoint has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with ...
EyePoint downgraded to Hold from Buy at TD Cowen
TD Cowen downgraded EyePoint (EYPT) to Hold from Buy with a price target of $4, down from $20. The company’s first Phase III wet age-related macular degeneration study failed, the…